Robert W. Baird started coverage on shares of GTx, Inc. (NASDAQ:GTXI) in a research report issued on Tuesday. The brokerage set an “outperform” rating and a $17.00 price target on the biopharmaceutical company’s stock. Robert W. Baird’s price target would indicate a potential upside of 52.88% from the company’s previous close.
Separately, Stifel Nicolaus started coverage on GTx in a report on Thursday, November 9th. They set a “buy” rating for the company.
GTx (NASDAQ GTXI) opened at $11.12 on Tuesday. GTx has a fifty-two week low of $2.73 and a fifty-two week high of $12.96.
GTx (NASDAQ:GTXI) last posted its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25). analysts expect that GTx will post -1.48 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Abingworth LLP acquired a new position in shares of GTx during the third quarter worth approximately $2,781,000. Caxton Corp acquired a new position in shares of GTx during the third quarter worth approximately $531,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of GTx during the second quarter worth approximately $124,000. Institutional investors and hedge funds own 9.02% of the company’s stock.
GTx Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.